US2021389310A1PendingUtilityA1

Oxidized cardiolipin as a pro-inflammatory factor

69
Assignee: ANNEXIN PHARMACEUTICALS ABPriority: Dec 19, 2008Filed: Mar 29, 2021Published: Dec 16, 2021
Est. expiryDec 19, 2028(~2.4 yrs left)· nominal 20-yr term from priority
A61K 38/1709G01N 2800/104A61P 9/00G01N 33/92C07K 16/18G01N 2800/24A61P 25/00A61P 9/10G01N 33/564A61P 19/02A61P 29/00C07K 2317/76A61P 9/12G01N 2800/324G01N 2800/2871A61P 25/28G01N 2800/50G01N 2800/32A61P 11/06G01N 33/5308A61P 3/10C07K 16/44
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Low levels of antibodies reactive with oxidised Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardivacular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunisation and therapy of these diseases and conditions are provided.

Claims

exact text as granted — not AI-modified
1 - 14 . (canceled) 
     
     
         15 . A method of treating, or reducing the risk of developing, an acute inflammatory condition in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of Annexin A5. 
     
     
         16 . The method according to  claim 15 , wherein the mammal is selecting from the list consisting of: a mouse, a rat, a rabbit, a dog, a cat, cattle, a horse, and a human. 
     
     
         17 . The method according to  claim 16 , wherein the mammal is a human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.